Altimmune ALT Income Taxes And Research Development Incentive Receivable Current
Income Taxes And Research Development Incentive Receivable Current at other companies
Other financials
Where this comes from
Reported directly by Altimmune in its filing.
Tagged under the XBRL concept alt:IncomeTaxesAndResearchDevelopmentIncentiveReceivableCurrent.
The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Altimmune's income taxes and research development incentive receivable current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Altimmune's income taxes and research development incentive receivable current?
- Altimmune (ALT) reported income taxes and research development incentive receivable current of $518K in Q4 2025.
- How has Altimmune's income taxes and research development incentive receivable current changed year-over-year?
- Altimmune's income taxes and research development incentive receivable current decreased by 79.9% year-over-year, from $2.57M to $518K.
- What is the long-term trend for Altimmune's income taxes and research development incentive receivable current?
- Over 5 years (2020 to 2025), Altimmune's income taxes and research development incentive receivable current has grown at a -41.8% compound annual growth rate (CAGR), from $7.76M to $518K.
- What does income taxes and research development incentive receivable current mean?
- This represents the current portion of tax credits or government-sponsored research and development incentives that the company expects to receive as a cash refund or offset against future tax liabilities. For a clinical-stage biotechnology firm, this asset reflects the monetization of R&D activities through regulatory tax frameworks. It serves as a non-dilutive source of liquidity that supports ongoing operational burn.